Dr. Bunn Discusses the Need to Study Drug Combinations in Lung Cancer

Video

Paul A. Bunn, Jr., MD, distinguished professor, University of Colorado, Lung Cancer: Giant of Cancer Care, discusses the need to study drug combinations in lung cancer.

Paul A. Bunn, Jr., MD, distinguished professor, University of Colorado, Lung Cancer: Giant of Cancer Care, discusses the need to study drug combinations in lung cancer.

The goal of early lung cancer pioneers, Bunn says, was to cure cancer with chemotherapies that shrank the disease. The strategy at the time was to combine drugs in order to get a complete remission that would last.

Today, lung cancer doctors have TKIs that are very specific and elicit high response rates – but they don’t cure anybody, Bunn says. There are many scientifically rational combinations that could be studied, he says, but these trials need to start happening.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
A panel of 5 experts on lung cancer